GSK halts development of chronic cough drug after late-stage trial failures

GSK is halting development of its chronic cough drug, camlipixant, after it failed in late-stage trials, sending shares down 4.5%. The drug, acquired in a $2B deal, was seen as key to GSK's £40B revenue target for 2031. While some analysts see the failure as manageable, it raises investor questions about the company's growth strategy and may increase pressure for new acquisitions.

Camlipixant trial failures

• ▪GSK will halt the development of its experimental drug, camlipixant, for treating refractory chronic cough
• ▪GSK will continue to test camlipixant as a treatment for irritable bowel syndrome
• ▪A lower 25 mg dose of the drug did not provide a clear benefit in either late-stage study
• ▪A 50 mg dose of camlipixant reduced coughing in one 12-week trial but failed to replicate the result in a second 24-week study
• ▪GSK stated the drug was "unlikely to transform patient care" due to its limited benefit in late-stage trials
• ▪GSK acquired camlipixant as part of its $2 billion acquisition of Bellus Health in 2023

GSK revenue targets

• ▪GSK has a target of £40 billion in annual revenue by 2031, which the company says it stands by
• ▪GSK had forecasted peak annual sales of about £2.5 billion for camlipixant, though analyst estimates were closer to £1 billion

Analyst reactions

• ▪Some analysts, such as Jefferies' Michael Leuchten, viewed the clinical failure as manageable for GSK's sales trajectory
• ▪JPMorgan analysts noted camlipixant was positioned to help close the gap between analyst forecasts and GSK's £40 billion revenue target for 2031

Investor concerns

• ▪The camlipixant program was seen as having an "above average risk of failing" because chronic cough is a difficult-to-treat disease
• ▪Markus Manns of shareholder Union Investment stated the failure could increase pressure on GSK for further acquisitions
• ▪Following the announcement on July 17, 2026, GSK's shares fell by as much as 4.5%

Refractory chronic cough condition

• ▪Refractory chronic cough affects nearly 10 million patients globally each year, who can cough more than 900 times a day
• ▪GSK plans to share the trial data to advance the scientific understanding of refractory chronic cough, a condition with limited treatment options